Abstract:Whole-genome sequencing (WGS) is increasingly favored over other genomic sequencing methods for clinical applications due to its comprehensive coverage and declining costs. WGS is particularly useful for the detection of copy number variants (CNVs), presumed to be more accurate than targeted sequencing assays such as WES or gene panels, because it can identify breakpoints in addition to changes in coverage depth. Recent advancements in bioinformatics tools, including those employing hardware acceleration and machine learning, have enhanced CNV detection. Although numerous benchmarking studies have been published, primarily focusing on open-source tools for short-read WGS CNV calling, systematic evaluations that encompass commercially available tools that meet the rigorous demands of clinical testing are still necessary. In clinical settings, where the confirmation of reported CNVs is often required, there is a higher priority on sensitivity over specificity/precision compared to research applications. Moreover, clinical gene panel reporting primarily concerns whether a CNV affects coding regions or, in some cases, promoters, rather than the precise detection of breakpoints. This study aims to benchmark the performance of various CNV detection tools tailored for clinical reporting from WGS using reference cell lines, providing insights critical for optimizing clinical diagnostics. Our results indicate that while different tools exhibit strengths in either sensitivity or precision and are better suited for certain classes and lengths of variants, few can deliver the balanced performance essential for clinical testing, where high sensitivity is imperative. Generally, callers demonstrate better performance for deletions than duplications, with the latter being poorly detected in events shorter than 5kb. We demonstrate that the DRAGEN™ v4.2 CNV caller, particularly with custom filters on its high sensitivity mode, offers a superior balance of sensitivity and precision compared to other available tools.

Systematic evaluation of de novo mutation calling tools using whole genome sequencing data

A Bayesian framework for de novo mutation calling in parents-offspring trios

Automated Identification of Germline de novo Mutations in Family Trios: A Consensus-Based Informatic Approach

A Gradient-Boosting Approach for Filtering De Novo Mutations in Parent-Offspring Trios

Comparative Analysis for the Performance of Variant Calling Pipelines on Detecting the De Novo Mutations in Humans

Benchmarking of Germline Copy Number Variant Callers from Whole Genome Sequencing Data for Clinical Applications

Automated Identification of Germline Mutations in Family Trios: A Consensus-Based Informatic Approach

An evaluation of copy number variation detection tools from whole-exome sequencing data.

An Integrated Approach for Copy Number Variation Discovery in Parent-Offspring Trios.

Customized De Novo Mutation Detection for Any Variant Calling Pipeline: SynthDNM.

Performance of Copy Number Variants Detection Based on Whole-Genome Sequencing by DNBSEQ Platforms

Benchmarking variant callers in next-generation and third-generation sequencing analysis

mirTrios: an integrated pipeline for detection of de novo and rare inherited mutations from trios-based next-generation sequencing.

A Statistical Framework for Mapping Risk Genes from De Novo Mutations in Whole-Genome-Sequencing Studies

Evaluation of tools for identifying large copy number variations from ultra-low-coverage whole-genome sequencing data

Systematic Comparative Analysis of Single-Nucleotide Variant Detection Methods from Single-Cell RNA Sequencing Data

A Comparison of Structural Variant Calling from Short-Read and Nanopore-Based Whole-Genome Sequencing Using Optical Genome Mapping as a Benchmark

DNMFilter_Indel: Filtering de novo Indels in Parent-Offspring Trios

Comparison of GATK and DeepVariant by trio sequencing

VizCNV: An integrated platform for concurrent phased BAF and CNV analysis with trio genome sequencing data

In-Depth Comparison of Somatic Point Mutation Callers Based on Different Tumor Next-Generation Sequencing Depth Data